Scarica l'app Stockscreener
0.8108
1.92%
0.0153
Dopo l'orario di chiusura:
.79
-0.0208
-2.57%
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
Rani Therapeutics CEO Imran Talat Withholds Shares for Tax on RSU Settlement - kalkinemedia.com
Form 4 Rani Therapeutics Holdings Inc Class A For: 29 September - Investing.com Nigeria
Tax withholding left Rani Therapeutics (RANI) CEO Imran Talat holding 461,808 shares. - Stock Titan
Stock-award tax withholding leaves Rani Therapeutics (RANI) CTO with 9,071 shares. - Stock Titan
Rani Therapeutics (RANI) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
RANI Stock Price, Quote & Chart - ChartMill
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN) - The Globe and Mail
Rani Therapeutics Holdings (RANI) Trades at $0.82, Holding a Narrow Sub-$1 RangeMerger Arbitrage - careplusvn.com
Rani Therapeutics at H.C. Wainwright: oral biologics gain traction By Investing.com - Investing.com UK
RANI: RaniPill's strong clinical data and major partnerships drive growth, with manufacturing and cash runway secured - TradingView
Rani Therapeutics (RANI) Institutional Ownership 2026 $RANI - MarketBeat
Rani Therapeutics Holdings, Inc. (RANI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rani Therapeutics will appear in New York on Sept. 10 and 14 - Stock Titan
Rani Therapeutics Holdings Stock Price Forecast. Should You Buy RANI? - StockInvest.us
Rani Therapeutics Holdings Inc (RANI) Peer Comparison – Compare with Others - Value Research
RANI Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pre-Revenue StageProfit Inflection Point - dars.gov.et
Rani Therapeutics Holdings Inc (RANI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Rani (RANI) Earnings Report: EPS Beats Its Estimate in Latest Trading; Trading Response: The Stock Gains 3.41% on the DayGuidance Accuracy Score - vinanet.vn
Rani (RANI) Trading: Finishes 3.41% Up at $0.88 in the Latest Session; Technical View: the Supplied Trading Band Runs From $0.84 to $0.92 in the Available RecordTWAP Entry - vinanet.vn
HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy - Investing.com
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely - webull.com
Chardan Capital Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues - Benzinga
Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Jump 9.5%Dividend Earnings Report - careplusvn.com
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics (RANI) Edges Lower to $0.80 as Stock Tests Crucial Support ZonePercent Below MA - vinanet.vn
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics (RANI) Edges Higher by 2.93% as Shares Approach Key $0.84 ResistanceFactor ETF Flow - dars.gov.et
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics appoints Michelle Gilson to board - The Globe and Mail
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics files Form 3 for director Michelle Gilson - Bitget
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
Rani Therapeutics appoints Michelle Gilson to board and as Audit Committee chair - TradingView
Rani Therapeutics Appoints Michelle Gilson to Board of Directors - Yahoo Finance
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics (RANI) Bounces 3.36% to $0.80 as Biotech Stock Holds SupportRetail Volume - careplusvn.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):